Gut 55(1): 115-122

Prostaglandins and cancer

D Wang, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

R N DuBois, Departments of Medicine, Cancer Biology, and Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN, USA, and The Vanderbilt‐Ingram Cancer Center, Nashville, TN, USA

Correspondence to: Professor R N DuBois
The Vanderbilt‐Ingram Cancer Center, Room 698, Preston Research Building, 2300 Pierce Ave, Nashville, Tennessee 37232‐6838, USA; raymond.dubois@vanderbilt.edu

D Wang, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USAR N DuBois, Departments of Medicine, Cancer Biology, and Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN, USA, and The Vanderbilt‐Ingram Cancer Center, Nashville, TN, USACorrespondence to: Professor R N DuBois
The Vanderbilt‐Ingram Cancer Center, Room 698, Preston Research Building, 2300 Pierce Ave, Nashville, Tennessee 37232‐6838, USA; raymond.dubois@vanderbilt.edu

Keywords: cyclooxygenase, prostaglandins, non‐steroidal anti‐inflammatory drugs, cancer, inflammation

Acknowledgements

We acknowledge support from the United States Public Health Services Grants RO1‐DK‐62112 and PO1‐CA77839. RND is the Hortense B Ingram Professor of Molecular Oncology and the recipient of an NIH MERIT award (R37‐DK47297). We also thank the TJ Martell Foundation and the National Colorectal Cancer Research Alliance (NCCRA) for generous support.

Acknowledgements

Footnotes

Conflict of interest: None declared.

Footnotes

References

1. Smalley W, DuBois R NColorectal cancer and non steroidal anti‐inflammatory drugs. Adv Pharmacol 1997391–20. [[PubMed][Google Scholar]
2. Gupta R A, Dubois R NColorectal cancer prevention and treatment by inhibition of cyclooxygenase‐2. Nat Rev Cancer 2001111–21. [[PubMed][Google Scholar]
3. Wolfe M M, Lichtenstein D R, Singh GGastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 19993401888–1899. [[PubMed][Google Scholar]
4. Vane J R, Bakhle Y S, Botting R MCyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 19983897–120. [[PubMed][Google Scholar]
5. Grover J K, Yadav S, Vats V. et al Cyclo‐oxygenase 2 inhibitors: emerging roles in the gut. Int J Colorectal Dis 200318279–291. [[PubMed]
6. Vane J RInhibition of prostaglandin synthesis as a mechanism of action for aspirin‐like drugs. Nature 1971231232–235. [[PubMed][Google Scholar]
7. Laine L, Harper S, Simon T. et al A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2‐specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999117776–783. [[PubMed]
8. Bombardier C, Laine L, Reicin A. et al Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 20003431520–1528. [[PubMed]
9. Silverman D G, Halaszynski T, Sinatra R. et al Rofecoxib does not compromise platelet aggregation during anesthesia and surgery. Can J Anaesth 2003501004–1008. [[PubMed]
10. Anderson W F, Umar A, Viner J L. et al The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 200281035–1062. [[PubMed]
11. Thun M J, Henley S J, Patrono CNonsteroidal anti‐inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 200294252–266. [[PubMed][Google Scholar]
12. Steinbach G, Lynch P M, Phillips R K. et al The effect of celecoxib, a cyclooxygenase‐2 inhibitor, in familial adenomatous polyposis. N Engl J Med 20003421946–1952. [[PubMed]
13. Solomon S D, McMurray J J, Pfeffer M A. et al Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 20053521071–1080. [[PubMed]
14. Bresalier R S, Sandler R S, Quan H. et al Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 20053521092–1102. [[PubMed]
15. Nussmeier N A, Whelton A A, Brown M T. et al Complications of the COX‐2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 20053521081–1091. [[PubMed]
16. Kuper H, Adami H O, Trichopoulos DInfections as a major preventable cause of human cancer. J Intern Med 2000248171–183. [[PubMed][Google Scholar]
17. Wang D, Mann J R, DuBois R NThe role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 20051281445–1461. [[PubMed][Google Scholar]
18. McAdam B F, Catella‐Lawson F, Mardini I A. et al Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)‐2: the human pharmacology of a selective inhibitor of COX‐2. Proc Natl Acad Sci U S A 199996272–277.
19. Grosser T, Yusuff S, Cheskis E. et al Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A 2002998418–8423.
20. Cha Y I, Kim S H, Solnica‐Krezel L. et al Cyclooxygenase‐1 signaling is required for vascular tube formation during development. Dev Biol 2005282274–283. [[PubMed]
21. DuBois R N, Abramson S B, Crofford L. et al Cyclooxygenase in biology and disease. FASEB J 1998121063–1073. [[PubMed]
22. Rigas B, Goldman I S, Levine LAltered eicosanoid levels in human colon cancer. J Lab Clin Med 1993122518–523. [[PubMed][Google Scholar]
23. Uefuji K, Ichikura T, Mochizuki HCyclooxygenase‐2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 20006135–138. [[PubMed][Google Scholar]
24. Rolland P H, Martin P M, Jacquemier J. et al Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980641061–1070. [[PubMed]
25. Needleman P, Isakson P CThe discovery and function of COX‐2. J Rheumatol 199724(suppl 49)6–8. [[PubMed][Google Scholar]
26. Portanova J P, Zhang Y, Anderson G D. et al Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996184883–891.
27. Anderson G D, Hauser S D, McGarity K L. et al Selective inhibition of cyclooxygenase (COX)‐2 reverses inflammation and expression of COX‐2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996972672–2679.
28. Amin A R, Attur M, Abramson S BNitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Curr Opin Rheumatol 199911202–209. [[PubMed][Google Scholar]
29. MacDermott R PAlterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med Clin North Am 1994781207–1231. [[PubMed][Google Scholar]
30. Gould S R, Brash A R, Conolly M E. et al Studies of prostaglandins and sulphasalazine in ulcerative colitis. Prostaglandins Med 19816165–182. [[PubMed]
31. Hansen‐Petrik M B, McEntee M F, Jull B. et al Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti‐inflammatory drug‐induced regression in Apc(Min/+) mice. Cancer Res 200262403–408. [[PubMed]
32. Kawamori T, Uchiya N, Sugimura T. et al Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 200324985–990. [[PubMed]
33. Wang D, Wang H, Shi Q. et al Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator‐activated receptor delta. Cancer Cell 20046285–295. [[PubMed]
34. Mukherjee D, Nissen S E, Topol E JRisk of cardiovascular events associated with selective COX‐2 inhibitors. JAMA 2001286954–959. [[PubMed][Google Scholar]
35. Adderley S R, Fitzgerald D JOxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2‐mediated induction of cyclooxygenase‐2. J Biol Chem 19992745038–5046. [[PubMed][Google Scholar]
36. Kashfi K, Rigas BNon‐COX‐2 targets and cancer: Expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 200570969–986. [[PubMed][Google Scholar]
37. Shureiqi I, Chen D, Lee J J. et al 15‐LOX‐1: a novel molecular target of nonsteroidal anti‐inflammatory drug‐induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000921136–1142. [[PubMed]
38. Zhang Z, DuBois R NPar‐4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 20001181012–1017. [[PubMed][Google Scholar]
39. Zhang L, Yu J, Park B H. et al Role of BAX in the apoptotic response to anticancer agents. Science 2000290989–992. [[PubMed]
40. Yamamoto Y, Yin M J, Lin K M. et al Sulindac inhibits activation of the NF‐kappaB pathway. J Biol Chem 199927427307–27314. [[PubMed]
41. Grilli M, Pizzi M, Memo M. et al Neuroprotection by aspirin and sodium salicylate through blockade of NF‐kappaB activation. Science 19962741383–1385. [[PubMed]
42. Pradono P, Tazawa R, Maemondo M. et al Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 20026263–66. [[PubMed]
43. Beuckmann C T, Fujimori K, Urade Y. et al Identification of mu‐class glutathione transferases M2‐2 and M3‐3 as cytosolic prostaglandin E synthases in the human brain. Neurochem Res 200025733–738. [[PubMed]
44. Jakobsson P J, Thoren S, Morgenstern R. et al Identification of human prostaglandin E synthase: a microsomal, glutathione‐dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999227220–7225.
45. Lazarus M, Munday C J, Eguchi N. et al Immunohistochemical localization of microsomal PGE synthase‐1 and cyclooxygenases in male mouse reproductive organs. Endocrinology 20021432410–2419. [[PubMed]
46. Tai H H, Ensor C M, Tong M. et al Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 200268–69483–493. [[PubMed]
47. Coggins K G, Latour A, Nguyen M S. et al Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med 2002891–92. [[PubMed]
48. Tong M, Tai H HSynergistic induction of the nicotinamide adenine dinucleotide‐linked 15‐hydroxyprostaglandin dehydrogenase by an androgen and interleukin‐6 or forskolin in human prostate cancer cells. Endocrinology 20041452141–2147. [[PubMed][Google Scholar]
49. Backlund M G, Mann J R, Holla V R. et al 15‐Hydroxyprostaglandin dehydrogenase is down‐regulated in colorectal cancer. J Biol Chem 20052803217–3223.
50. Yan M, Rerko R M, Platzer P. et al 15‐Hydroxyprostaglandin dehydrogenase, a COX‐2 oncogene antagonist, is a TGF‐beta‐induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 200410117468–17473.
51. Ding Y, Tong M, Liu S. et al NAD+‐linked 15‐hydroxyprostaglandin dehydrogenase (15‐PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 20052665–72. [[PubMed]
52. Gee J R, Montoya R G, Khaled H M. et al Cytokeratin 20, AN43, PGDH, and COX‐2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 200321266–270. [[PubMed]
53. Quidville V, Segond N, Pidoux E. et al Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15‐hydroxyprostaglandin dehydrogenase. Endocrinology 20041452561–2571. [[PubMed]
54. Watanabe K, Kawamori T, Nakatsugi S. et al Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999595093–5096. [[PubMed]
55. Mutoh M, Watanabe K, Kitamura T. et al Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 20026228–32. [[PubMed]
56. Sonoshita M, Takaku K, Sasaki N. et al Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcDelta716 knockout mice. Nat Med 200171048–1051. [[PubMed]
57. Chang S H, Liu C H, Conway R. et al Role of prostaglandin E2‐dependent angiogenic switch in cyclooxygenase 2‐induced breast cancer progression. Proc Natl Acad Sci U S A 2004101591–596.
58. Kawamori T, Uchiya N, Nakatsugi S. et al Chemopreventive effects of ONO‐8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis 2001222001–2004. [[PubMed]
59. Amano H, Hayashi I, Endo H. et al Host prostaglandin E(2)‐EP3 signaling regulates tumor‐associated angiogenesis and tumor growth. J Exp Med 2003197221–232.
60. Kelloff G, Fay J, Steele V. et al Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 19965657–666. [[PubMed]
61. Yoshimoto T, Takahashi Y, Kinoshita T. et al Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase‐overexpressing human colon carcinoma cells. Adv Exp Med Biol 2002507403–407. [[PubMed]
62. Sheng H, Shao J, Washington M K. et al Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 200127618075–18081. [[PubMed]
63. Buchanan F G, Wang D, Bargiacchi F. et al Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 200327835451–35457. [[PubMed]
64. Pai R, Soreghan B, Szabo I L. et al Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 20028289–293. [[PubMed]
65. Radinsky RModulation of tumor cell gene expression and phenotype by the organ‐specific metastatic environment. Cancer Metastasis Rev 199514323–338. [[PubMed][Google Scholar]
66. Mann M, Sheng H, Shao J. et al Targeting cyclooxygenase 2 and her‐2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 20011201713–1719. [[PubMed]
67. Tortora G, Caputo R, Damiano V. et al Combination of a selective cyclooxygenase‐2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 200391566–1572. [[PubMed]
68. Torrance C J, Jackson P E, Montgomery E. et al Combinatorial chemoprevention of intestinal neoplasia. Nat Med 200061024–1028. [[PubMed]
69. Moran A E, Hunt D H, Javid S H. et al Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J‐Min/+ mice. J Biol Chem 200427943261–43272. [[PubMed]
70. Wang Y X, Lee C H, Tiep S. et al Peroxisome‐proliferator‐activated receptor delta activates fat metabolism to prevent obesity. Cell 2003113159–170. [[PubMed]
71. Tanaka T, Yamamoto J, Iwasaki S. et al Activation of peroxisome proliferator‐activated receptor delta induces fatty acid beta‐oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 200310015924–15929.
72. He T C, Chan T A, Vogelstein B. et al PPARdelta is an APC‐regulated target of nonsteroidal anti‐inflammatory drugs. Cell 199999335–345.
73. Gupta R A, Wang D, Katkuri S. et al Activation of nuclear hormone receptor peroxisome proliferator‐activated receptor‐delta accelerates intestinal adenoma growth. Nat Med 200410245–247. [[PubMed]
74. Sheng G G, Shao J, Sheng H. et al A selective cyclooxygenase 2 inhibitor suppresses the growth of H‐ras‐transformed rat intestinal epithelial cells. Gastroenterology 19971131883–1891. [[PubMed]
75. Sheng H, Williams C S, Shao J. et al Induction of cyclooxygenase‐2 by activated Ha‐ras oncogene in Rat‐1 fibroblasts and the role of mitogen‐activated protein kinase pathway. J Biol Chem 199827322120–22127. [[PubMed]
76. Subbaramaiah K, Telang N, Ramonetti J T. et al Transcription of cyclooxygenase‐2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996564424–4429. [[PubMed]
77. Heasley L E, Thaler S, Nicks M. et al Induction of cytosolic phospholipase A2 by oncogenic Ras in human non‐small cell lung cancer. J Biol Chem 199727214501–14504. [[PubMed]
78. Wong B C, Jiang X H, Lin M C. et al Cyclooxygenase‐2 inhibitor (SC‐236) suppresses activator protein‐1 through c‐Jun NH2‐terminal kinase. Gastroenterology 2004126136–147. [[PubMed]
79. Husain S S, Szabo I L, Pai R. et al MAPK (ERK2) kinase—a key target for NSAIDs‐induced inhibition of gastric cancer cell proliferation and growth. Life Sci 2001693045–3054. [[PubMed]
80. Gala M, Sun R, Yang V WInhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways. Cancer Lett 200217589–94. [Google Scholar]
81. Wang D, Buchanan F G, Wang H. et al Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras‐mitogen‐activated protein kinase cascade. Cancer Res 2005651822–1829. [[PubMed]
82. Iniguez M A, Rodriguez A, Volpert O V. et al Cyclooxygenase‐2: a therapeutic target in angiogenesis. Trends Mol Med 2003973–78. [[PubMed]
83. Tsujii M, Kawano S, Tsuji S. et al Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 199893705–716. [[PubMed]
84. Masferrer J L, Leahy K M, Koki A T. et al Antiangiogenic and antitumor activities of cyclooxygenase‐2 Inhibitors. Cancer Res 2000601306–1311. [[PubMed]
85. Skopinska‐Rozewska E, Piazza G A, Sommer E. et al Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN‐1): a potential mechanism for their antineoplastic properties. Int J Tissue React 19982085–89. [[PubMed]
86. Sawaoka H, Tsuji S, Tsujii M. et al Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999791469–1477. [[PubMed]
87. Hernandez G L, Volpert O V, Iniguez M A. et al Selective inhibition of vascular endothelial growth factor‐mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001193607–620.
88. Trompezinski S, Pernet I, Schmitt D. et al UV radiation and prostaglandin E2 up‐regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm Res 200150422–427. [[PubMed]
89. Pai R, Szabo I L, Soreghan B A. et al PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001286923–928. [[PubMed]
90. Spinella F, Rosano L, Di Castro V. et al Endothelin‐1‐induced prostaglandin E2‐EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 200427946700–46705. [[PubMed]
91. Bradbury D A, Clarke D L, Seedhouse C. et al Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP‐1 transcription factor binding sites. J Biol Chem 200528029993–30000. [[PubMed]
92. Kage K, Fujita N, Oh‐hara T. et al Basic fibroblast growth factor induces cyclooxygenase‐2 expression in endothelial cells derived from bone. Biochem Biophys Res Commun 1999254259–263. [[PubMed]
93. Tsujii M, DuBois R NAlterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase‐2. Cell 199583493–501. [[PubMed][Google Scholar]
94. Sheng H, Shao J, Morrow J. et al Modulation of apoptosis by prostaglandin treatment in human colon cancer cells. Cancer Res 199858362–366. [[PubMed]
95. Poligone B, Baldwin A SPositive and negative regulation of NF‐kappaB by COX‐2: roles of different prostaglandins. J Biol Chem 200127638658–38664. [[PubMed][Google Scholar]
96. Davis T W, O'Neal J M, Pagel M D. et al Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase‐2‐derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 200464279–285. [[PubMed]
97. Balkwill FCancer and the chemokine network. Nat Rev Cancer 20044540–550. [[PubMed][Google Scholar]
98. Jing H, Vassiliou E, Ganea DProstaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. J Leukoc Biol 200374868–879. [[PubMed][Google Scholar]
99. Jing H, Yen J H, Ganea DA novel signaling pathway mediates the inhibition of CCL3/4 expression by PGE2. J Biol Chem 200427955176–55186. [[PubMed][Google Scholar]
100. Takayama K, Garcia‐Cardena G, Sukhova G K. et al Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 200227744147–44154. [[PubMed]
101. Balkwill F, Mantovani AInflammation and cancer: back to Virchow? Lancet 2001357539–545. [[PubMed][Google Scholar]
102. Bottazzi B, Polentarutti N, Acero R. et al Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983220210–212. [[PubMed]
103. Salcedo R, Zhang X, Young H A. et al Angiogenic effects of prostaglandin E2 are mediated by up‐regulation of CXCR4 on human microvascular endothelial cells. Blood 20031021966–1977. [[PubMed]
104. Liang Z, Yoon Y, Votaw J. et al Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 200565967–971.
105. Hart C A, Brown M, Bagley S. et al Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer 200592503–512.
106. Eisenhardt A, Frey U, Tack M. et al Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol 200547111–117. [[PubMed]
107. Marchesi F, Monti P, Leone B E. et al Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004648420–8427. [[PubMed]
108. Stolina M, Sharma S, Lin Y. et al Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL‐10 and IL‐12 synthesis. J Immunol 2000164361–370. [[PubMed]
109. Yao M, Kargman S, Lam E C. et al Inhibition of cyclooxygenase‐2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 200363586–592. [[PubMed]
110. Harris S G, Padilla J, Koumas L. et al Prostaglandins as modulators of immunity. Trends Immunol 200223144–150. [[PubMed]
111. Shreedhar V, Giese T, Sung V W. et al A cytokine cascade including prostaglandin E2, IL‐4, and IL‐10 is responsible for UV‐induced systemic immune suppression. J Immunol 19981603783–3789. [[PubMed]
112. Huang M, Stolina M, Sharma S. et al Non‐small cell lung cancer cyclooxygenase‐2‐dependent regulation of cytokine balance in lymphocytes and macrophages: up‐regulation of interleukin 10 and down‐regulation of interleukin 12 production. Cancer Res 1998581208–1216. [[PubMed]
113. Della Bella S, Molteni M, Compasso S. et al Differential effects of cyclo‐oxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukot Essent Fatty Acids 199756177–184. [[PubMed]
114. Yang L, Yamagata N, Yadav R. et al Cancer‐associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003111727–735.
115. Goodwin J S, Ceuppens JRegulation of the immune response by prostaglandins. J Clin Immunol 19833295–315. [[PubMed][Google Scholar]
116. Holla V R, Wang D, Brown J R. et al Prostaglandin E2 regulates the complement inhibitor CD55/decay‐accelerating factor in colorectal cancer. J Biol Chem 2005280476–483. [[PubMed]